Methods In this open-label phase II study patients with histologically confirmed HCC and CCA were treated with 300 mg tremelimumab, 7.5 mg/kg bevacizumab and 1150 mg durvalumab on day 1 followed by 7.5 mg/kg bevacizumab and 1150 mg durvalumab every 3 weeks. Primary objective was the 6-month...